Artiva Biotherapeutics, Inc.
ARTV
$2.88
$0.113.97%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -100.00% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -100.00% | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -100.00% | -- | -- |
| SG&A Expenses | 28.31% | 42.71% | 56.30% | 73.06% | -4.98% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 40.89% | 50.38% | 27.56% | 15.71% | 5.67% |
| Operating Income | -40.89% | -52.99% | -52.61% | -269.60% | -36.92% |
| Income Before Tax | -19.12% | -45.46% | -34.96% | -254.91% | -58.13% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -19.12% | -45.46% | -34.15% | -254.91% | -58.13% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -19.12% | -45.46% | -34.15% | -254.91% | -58.13% |
| EBIT | -40.89% | -52.99% | -52.61% | -269.60% | -36.92% |
| EBITDA | -42.23% | -54.93% | -55.18% | -255.78% | -38.11% |
| EPS Basic | 96.04% | 95.16% | 95.55% | -106.61% | -56.11% |
| Normalized Basic EPS | 96.04% | 95.16% | 95.28% | -106.61% | -56.12% |
| EPS Diluted | 96.04% | 95.16% | 95.54% | -157.07% | -56.11% |
| Normalized Diluted EPS | 96.04% | 95.16% | 95.28% | -157.12% | -56.12% |
| Average Basic Shares Outstanding | 2,905.28% | 2,905.93% | 2,912.80% | 2,242.48% | 1.29% |
| Average Diluted Shares Outstanding | 2,905.28% | 2,905.93% | 2,912.80% | 171.23% | 1.29% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |